
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics is attractive because ficerafusp alfa combines EGFR and TGF-β blockade in a single asset, with early data showing deep, durable responses and a clean safety profile that could translate into a differentiated standard-of-care position in HPV-negative R/M HNSCC. Despite Genmab’s strong LiGeR-HN1 readout raising the competitive bar, management says FORTIFI-HN01 is substantially enrolled, the mid-2027 interim remains on track, and the company also has FORTIFI-FLEX plus 3L+ mCRC data expected in January 2027, preserving multiple catalysts. Financially, the company has cash runway into 1H29, while the modeled opportunity is meaningful, including about $1.3 billion in peak sales and $909 million in peak risk-adjusted sales in the US and EU for the lead indication.
Bears say
Bicara Therapeutics is exposed to a challenging commercial and clinical landscape because the model update points to higher-than-expected 3Q R&D and SG&A, signaling escalating operating expense pressure before the company has established meaningful revenue. The competitive position also looks weak, as petosemtamab is described as achieving a first-to-market advantage and capturing prescribing patterns well ahead of ficerafusp alfa, while amivantamab is showing strong activity. Together, these factors suggest Bicara may face a slower and more expensive path to market, with increased dilution risk and a tougher bar for ficerafusp alfa to gain share in solid tumors.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Bicara Therapeutics Inc (BCAX) Forecast
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares